

Appendices

PART SIX: APPENDICES

Part Six provides supplementary operational information. This section contains financial statements, mandatory reporting requirements, including the Freedom of Information Statement, and a comprehensive list of blood and blood-related products procured under contracts and deeds.

Appendix 1 Financial statements

Appendix 2 Freedom of Information Statement

Appendix 3 Blood products supplied by the Australian Red Cross Blood Service

Appendix 4 Plasma products supplied under contract



Appendix 1: Financial statements



INDEPENDENT AUDITOR'S REPORT

To the Minister for Health and Ageing

Scope

I have audited the accompanying financial statements of the National Blood Authority for the year ended 30 June 2007, which comprise: a statement by the Chief Executive and Chief Finance Officer; income statement; balance sheet; statement of changes in equity; cash flow statement; schedules of commitments, contingencies and administered items; a summary of significant accounting policies; and other explanatory notes.

The Responsibility of the Chief Executive for the Financial Statements

The National Blood Authority's Chief Executive is responsible for the preparation and fair presentation of the financial statements in accordance with the Finance Minister's Orders made under the *Financial Management and Accountability Act 1997* and the Australian Accounting Standards (including the Australian Accounting Interpretations). This responsibility includes establishing and maintaining internal controls relevant to the preparation and fair presentation of the financial statements that are free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility

My responsibility is to express an opinion on the financial statements based on my audit. My audit has been conducted in accordance with the Australian National Audit Office Auditing Standards, which incorporate the Australian Auditing Standards. These Auditing Standards require that I comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the National Blood Authority's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the National Blood Authority's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the National Blood Authority's Chief Executive, as well as evaluating the overall presentation of the financial statements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my audit opinion.

Independence


In conducting the audit, I have followed the independence requirements of the Australian National Audit Office, which incorporate the ethical requirements of the Australian accounting profession.

Auditor's Opinion

In my opinion, the financial statements of the National Blood Authority:

- (a) have been prepared in accordance with the Finance Minister's Orders made under the *Financial Management and Accountability Act 1997*, and the Australian Accounting Standards (including the Australian Accounting Interpretations); and
- (b) give a true and fair view of the matters required by the Finance Minister's Orders including the National Blood Authority's financial position as at 30 June 2007 and of its financial performance and its cash flows for the year then ended.

Australian National Audit Office


John McCullough
Acting Executive Director
Delegate of the Auditor-General

Canberra
14 August 2007

**National Blood Authority
Financial Statements
For the year ended 30 June 2007**

Statement by the Chief Executive Officer and Chief Finance Officer

In our opinion, the attached financial statements for the year ended 30 June 2007 have been prepared based on properly maintained financial records and give a true and fair view of the matters required by the Finance Minister's Orders made under the *Financial Management and Accountability Act 1997*, as amended.



Signed

.....
A J Turner
Chief Executive Officer

14 August 2007



Signed

.....
S J Cochrane
Chief Finance Officer

14 August 2007

**NATIONAL BLOOD AUTHORITY
INCOME STATEMENT**

for the year ended 30 June 2007

	Notes	2007 \$'000	2006 \$'000
INCOME			
Revenue			
Revenues from Government	3A	6 065	4 532
Sales of goods and rendering of services	3B	4 064	3 570
Total revenue		10 129	8 102
Gains			
Other gains	3C	96	91
Total gains		96	91
Total income		10 225	8 193
Operating expenses			
Employee benefits	4A	5 712	4 859
Suppliers	4B	2 941	2 395
Depreciation and amortisation	4C	284	285
Write-down and impairment of assets	4D	111	83
Losses from asset sales	4E	11	6
Total expenses		9 059	7 628
Surplus		1 166	565

NATIONAL BLOOD AUTHORITY
BALANCE SHEET
as at 30 June 2007

	Notes	2007 \$'000	2006 \$'000
ASSETS			
Financial assets			
Cash	5A,9	53	61
Trade and other receivables	5B	9 242	7 755
Total financial assets		9 295	7 816
Non-financial assets			
Leasehold improvements	6A, 6E	228	324
Infrastructure, plant and equipment	6B, 6E	240	317
Intangibles	6C, 6E	805	120
Other non-financial assets	6D	17	8
Total non-financial assets		1 290	769
Total assets		10 585	8 585
LIABILITIES			
Payables			
Suppliers	7A	659	498
Other payables	7B	3 691	3 483
Total payables		4 350	3 981
Provisions			
Employee provisions	8	969	904
Total provisions		969	904
Total liabilities		5 319	4 885
NET ASSETS		5 266	3 700
EQUITY			
Reserves		15	21
Contributed equity		812	406
Retained surplus		4 439	3 273
TOTAL EQUITY		5 266	3 700
Current assets		9 312	7 824
Non-current assets		1 273	761
Current liabilities		5 040	4 767
Non-current liabilities		279	118

6: Appendices

**NATIONAL BLOOD AUTHORITY
STATEMENT OF CHANGES IN EQUITY**
for the year ended 30 June 2007

Item	Accumulated Results		Asset Revaluation Reserve		Contributed Equity/Capital		Total Equity	
	2006-07 \$'000	2005-06 \$'000	2006-07 \$'000	2005-06 \$'000	2006-07 \$'000	2005-06 \$'000	2006-07 \$'000	2005-06 \$'000
Opening balance								
Balance carried forward from previous period	3 273	2 708	21	34	406	-	3 700	2 742
Adjustment for errors	-	-	-	-	-	-	-	-
Adjustment for changes in accounting policy	-	-	-	-	-	-	-	-
Adjusted opening balance	3 273	2 708	21	34	406	-	3 700	2 742
Income and expense								
Revaluation adjustment	-	-	(6)	(13)	-	-	(6)	(13)
Subtotal income and expenses recognised directly in equity	3 273	2 708	15	21	406	-	3 694	2 729
Surplus for the year	1 166	565	-	-	-	-	1 166	565
Total income and expenses	4 439	3 273	15	21	406	-	4 860	3 294
of which:								
attributable to Australian Government	4 439	3 273	15	21	-	-	4 454	3 294
attributable to outside equity interest	-	-	-	-	-	-	-	-
Transactions with owners								
Contributions by owners	-	-	-	-	-	-	-	-
Appropriation (equity injection)	-	-	-	-	406	406	406	406
Subtotal transactions with owners	-	-	-	-	406	406	406	406
Transfers between equity components	-	-	-	-	-	-	-	-
Closing balance at 30 June	4 439	3 273	15	21	812	406	5 266	3 700

The above statement should be read in conjunction with the accompanying notes

**NATIONAL BLOOD AUTHORITY
STATEMENT OF CASHFLOWS**
for the year ended 30 June 2007

	Notes	2007 \$'000	2006 \$'000
OPERATING ACTIVITIES			
Cash received			
Appropriations		6 065	6 229
Goods and services		4 053	4 161
Net GST received		381	297
Total cash received		10 499	10 687
Cash used			
Employees		5 692	5 064
Suppliers		3 182	2 417
Total cash used		8 874	7 481
Net cash from operating activities	9	1 625	3 206
INVESTING ACTIVITIES			
Cash used			
Purchase of infrastructure, plant and equipment		171	336
Purchase of intangibles - work in progress		669	-
Total cash used		840	336
Net cash used by investing activities		(840)	(336)
FINANCING ACTIVITIES			
Cash received			
Appropriations - contributed equity		495	-
Total cash received		495	-
Net cash from financing activities		495	-
Net increase in cash held		1 280	2 870
Cash at the beginning of the reporting period		61	4 485
Cash transferred to the Official Public Account		(1 288)	(7 294)
Cash at end of the reporting period	5A	53	61

6: Appendices

**NATIONAL BLOOD AUTHORITY
SCHEDULE OF COMMITMENTS AND CONTINGENCIES**

as at 30 June 2007

	2007 \$'000	2006 \$'000
COMMITMENTS		
BY TYPE		
Capital commitments		
Infrastructure, plant and equipment	954	-
Other capital commitments	661	-
Total capital commitments	1 615	-
Other commitments		
Operating leases	994	1 406
Other commitments	1 172	440
Total other commitments	2 166	1 846
Commitments receivable		
GST receivable	344	168
Total commitments receivable	344	168
Net commitments by type	3 437	1 678
BY MATURITY		
Capital commitments		
One year or less	1 615	-
From one to five years	-	-
Total goods and service contracts	1 615	-
Other commitments		
One year or less	1 312	785
From one to five years	854	1 061
Total operating lease commitments	2 166	1 846
Commitments receivable		
One year or less	266	71
From one to five years	78	97
Total commitments receivable	344	168
Net commitments by maturity	3 437	1 678

NB. All commitments are stated inclusive of Goods and Services Tax where relevant.

Operating leases included are effectively non cancellable and comprise:

6: Appendices

**NATIONAL BLOOD AUTHORITY
SCHEDULE OF COMMITMENTS AND CONTINGENCIES**

as at 30 June 2007

Nature of lease	General description of leasing arrangement
Lease for office accommodation	The current lease for office accommodation expires on 31 October 2009.
Agreements for the provision of motor vehicles to senior executive officers	Non-contingent rentals exist. There are no renewal or purchase options available to the Authority.

CONTINGENT LIABILITIES AND ASSETS

Remote Contingencies

The Australian Government has indemnified the lessor of the National Blood Authority's premises for negligent acts committed by the National Blood Authority up to the value of \$1,000,000.

Unquantifiable Contingencies

The National Blood Authority office accommodation sustained water damage in February 2007 following a hail storm that affected many buildings in Canberra city. The initial insurance claim has been submitted to Comcover for approval and subsequent payment. To date the NBA has been advised that approximately \$213,000 has been validated and this has been accrued in 2006-07. The NBA is still waiting for replacement office furniture to be delivered and it expected that this will be available in August 2007 at which time the claim will be further assessed by Comcover.

**NATIONAL BLOOD AUTHORITY
SCHEDULE OF COMMITMENTS AND CONTINGENCIES**

as at 30 June 2007

	Notes	2007 \$'000	2006 \$'000
Income administered on behalf of Government			
<i>for the year ended 30 June 2007</i>			
Revenue			
Non-taxation revenues			
State and Territory contributions	15	223 957	213 875
Other sources of non-taxation revenues	15	22 990	3 200
Total non-taxation revenues		246 947	217 075
Total revenues administered on behalf of Government		246 947	217 075
Expenses administered on behalf of Government			
<i>for the year ended 30 June 2007</i>			
Grants	16	305 770	299 296
Suppliers	16	303 080	266 843
Total expenses administered on behalf of Government		608 850	566 139
Financial assets			
Cash	17A	-	-
Receivables	17B	8 375	12 087
Non-financial assets			
Inventory	17C	65 249	49 066
Other non-financial assets	17D	10 071	-
Total assets administered on behalf of Government		83 695	61 153
Liabilities administered on behalf of Government			
<i>as at 30 June 2007</i>			
Payables			
Suppliers	18A	28 331	54 689
Unearned income	18B	37 014	24 893
Total liabilities administered on behalf of Government		65 345	79 582
Net assets administered on behalf of Government	19	18 350	(18 429)
Current assets		83 695	61 153
Non-current assets		-	-
Current liabilities		65 345	79 582
Non-current liabilities		-	-

6: Appendices

**NATIONAL BLOOD AUTHORITY
SCHEDULE OF ADMINISTERED ITEMS (continued)**

	2007 \$'000	2006 \$'000
Administered Cash Flows		
<i>for the year ended 30 June 2007</i>		
OPERATING ACTIVITIES		
Cash received		
State and Territory contributions	237 644	219 556
Other - GST received from ATO	63 344	52 960
Other	-	3 406
Total cash received	<u>300 988</u>	<u>275 922</u>
Cash used		
Grants	336 347	304 067
Suppliers	363 323	283 078
Total cash used	<u>699 670</u>	<u>587 145</u>
Net cash used by operating activities	<u>(398 682)</u>	<u>(311 223)</u>
Net increase in cash held	<u>(398 682)</u>	<u>(311 223)</u>
Cash at the beginning of the reporting period	-	-
Cash from Official Public Account for: Special account	<u>699 670</u>	<u>587 145</u>
	<u>699 670</u>	<u>587 145</u>
Cash to Official Public Account for: Special account	<u>300 988</u>	<u>275 922</u>
	<u>300 988</u>	<u>275 922</u>
Cash at end of the reporting period	<u>-</u>	<u>-</u>
BY TYPE		
Other commitments ¹		
Other commitments	<u>1 606 633</u>	<u>1 096 341</u>
Total other commitments	<u>1 606 633</u>	<u>1 096 341</u>
Commitments receivable		
GST receivable	<u>146 058</u>	<u>99 667</u>
Total commitments receivable	<u>146 058</u>	<u>99 667</u>
Net commitments	<u>1 460 575</u>	<u>996 674</u>

¹ Other commitments relate to amounts payable under agreements and contracts in respect of which the grantee or supplier has yet to provide services required under the agreement or contract.

**NATIONAL BLOOD AUTHORITY
SCHEDULE OF COMMITMENTS AND CONTINGENCIES**

as at 30 June 2007

	2007 \$'000	2006 \$'000
BY MATURITY		
Other commitments		
One year or less	692 831	353 923
From one to five years	913 802	742 418
Total other commitments	1 606 633	1 096 341
Commitments receivable		
One year or less	62 985	32 175
From one to five years	83 073	67 492
Total commitments receivable	146 058	99 667
Net commitments by maturity	1 460 575	996 674

NB: All commitments are GST inclusive where relevant

There were no quantifiable administered contingent liabilities as at 30 June 2007.

Unquantifiable and remote but material contingencies are disclosed in **Note 20: Administered Contingent Liabilities**

Statement of Activities Administered on Behalf of Government

The major activities of the National Blood Authority are directed towards managing national blood arrangements, ensuring sufficient supply and to provide a new focus on the safety and quality of blood products and services.

The NBA manages and coordinates Australia's blood supply in accordance with the National Blood Agreement agreed by the Commonwealth, States and Territories. Under this agreement, the Commonwealth contributes 63 per cent of overall costs in the blood sector and the States and Territories are providing 37 per cent. The funding for blood and blood products is funded from a special account established under the National Blood Authority Act 2003. The Act also established a special appropriation held by the Department of Health and Ageing, under the Financial Management and Accountability Act 1997.

Details of planned activities for the year can be found in the Agency Portfolio Budget and Portfolio Additional Estimates for 2006-07 which have been tabled in Parliament.

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

INDEX

NOTE 1	Summary of Significant Accounting Policies
NOTE 2	Events after the Balance Sheet Date
NOTE 3	Income
NOTE 4	Operating Expenses
NOTE 5	Financial Assets
NOTE 6	Non Financial Assets
NOTE 7	Payables
NOTE 8	Provisions
NOTE 9	Cash Flow Reconciliation
NOTE 10	Remuneration of Executives
NOTE 11	Remuneration of Auditors
NOTE 12	Average Staffing Levels
NOTE 13	Contingent Liabilities and Assets
NOTE 14	Financial Instruments
NOTE 15	Income Administered on Behalf of Government
NOTE 16	Expenses Administered on Behalf of Government
NOTE 17	Assets Administered on Behalf of Government
NOTE 18	Liabilities Administered on Behalf of Government
NOTE 19	Administered Reconciliation Table
NOTE 20	Administered Contingent Liabilities and Assets
NOTE 21	Administered Financial Instruments
NOTE 22	Appropriations
NOTE 23	Special Accounts
NOTE 24	Compensation and Debt Relief
NOTE 25	Reporting of Outcomes

**NATIONAL BLOOD AUTHORITY
SCHEDULE OF COMMITMENTS AND CONTINGENCIES**

as at 30 June 2007

NOTE 1 Summary of Significant Accounting Policies

1.1 Objectives of the National Blood Authority

The National Blood Authority (NBA) was established on 1 July 2003 with the principal role of managing national blood arrangements, ensuring sufficient supply and to provide a new focus on the quality and appropriateness of blood products.

The NBA manages and coordinates Australia’s blood supply in accordance with the National Blood Agreement agreed by the Australian Government, States and Territories. Under this agreement, the Australian Government contributes 63 per cent of overall costs in the blood sector and the States and Territories provide 37 per cent. The funding for blood and blood products is funded from a special account established under the *National Blood Authority Act 2003*. This Act also established a special appropriation held by the Department of Health and Ageing, under the *Financial Management and Accountability Act 1997*.

The Authority contributes to the Department of Health and Ageing Portfolio Outcome 13 - Acute Care, under the following outcome and outcome group:

Outcome	Administered Items and Output Groups
Australia’s blood supply is secure and well managed.	Output Group 1 – Meet product demand through effective planning and the management of supply arrangements.

The NBA’s activities contributing to this outcome are classified as either Departmental or Administered. Departmental activities involve the use of assets, liabilities, revenues and expenses controlled by the NBA in its own right. Administered activities involve the management or oversight by the NBA, on behalf of the Government, of items controlled or incurred by the Government.

The continued existence of the NBA in its present form, and with its present programs, is dependent on Government policy and on continuing appropriations by Parliament and contributions from States and Territories for the NBA’s administration and programs.

1.2 Basis of Preparation of the Financial Statements

The financial statements and notes are required by Section 49 of Schedule 1 to the *Financial Management and Accountability Act 1997* and are a General Purpose Financial Report.

The financial statements and notes have been prepared in accordance with:

- Finance Minister’s Orders for reporting periods ending on or after 1 July 2006; and
- Australian Accounting Standards and Accounting Interpretations issued by the Australian Accounting Standards Board (AASB) that apply for the reporting period.

The financial report has been prepared on an accrual basis and in accordance with historical cost convention, except for certain assets, which, as noted, are at fair value. Except where stated, no allowance is made for the effect of changing prices on the results or the financial position.

6: Appendices

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

The financial report is presented in Australian dollars and values are rounded to the nearest thousand dollars unless disclosure of the full amount is specifically required.

Unless an alternative treatment is specifically required by an accounting standard or the Finance Minister's Orders, assets and liabilities are recognised in the Balance Sheet when and only when it is probable that future economic benefits will flow to the NBA and the amounts of the assets or liabilities can be reliably measured. However, assets and liabilities arising under agreements equally proportionately unperformed are not recognised unless required by an Accounting Standard. Liabilities and assets that are unrealised are reported in the Schedule of Commitments and the Schedule of Contingencies (other than unquantifiable or remote contingencies, which are reported at Note 13).

Unless an alternative treatment is specifically required by an accounting standard, revenues and expenses are recognised in the Income Statement when and only when the flow, consumption or loss of economic benefits has occurred and can be reliably measured.

Administered revenues, expenses, assets and liabilities and cash flows reported in the Schedule of Administered Items and related notes are accounted for on the same basis and using the same policies as for Departmental items.

1.3 Significant Accounting Judgments and Estimates

No accounting assumptions or estimates have been identified that have a significant risk of causing a material adjustment to carrying amounts of assets and liabilities within the next accounting period.

1.4 Statement of Compliance

The Australian Accounting Standards require a statement of compliance with International Financial Reporting Standards (IFRSs) to be made where the financial report complies with these standards. Some Australian equivalents to IFRSs and other Australian Accounting Standards contain requirements specific to not-for-profit entities that are inconsistent with IFRS requirements. The NBA is a not for profit entity and has applied these requirements, so while this financial report complies with Australian Accounting Standards including Australian Equivalents to International Financial Reporting Standards (AEIFRSs) it cannot make this statement.

Adoption of new Australian Accounting Standard requirements

No accounting standard has been adopted earlier than the effective date in the current period.

The following adopted requirements have resulted in a change to the NBA's accounting policies or have affected the amounts reported in the current or prior periods or are estimated to have a financial affect in future reporting periods.

Other effective requirement changes

The following amendments, revised standards or interpretations have become effective but have had no financial impact or do not apply to the operations of the NBA.

NATIONAL BLOOD AUTHORITY SCHEDULE OF COMMITMENTS AND CONTINGENCIES

as at 30 June 2007

Amendments:

- 2005-1 Amendments to Australian Accounting Standards [AASBs 1, 101, 124]
- 2005-4 Amendments to Australian Accounting Standards [AASB 139, AASB 132, AASB 1, AASB 1023 and AASB 1038]
- 2005-5 Amendments to Australian Accounting Standards [AASB 1 & AASB 139]
- 2005-6 Amendments to Australian Accounting Standards [AASB 3]
- 2005-9 Amendments to Australian Accounting Standards [AASB 4, AASB 1023, AASB 139 & AASB 132]
- 2006-1 Amendments to Australian Accounting Standards [AASB 121]
- 2006-3 Amendments to Australian Accounting Standards [AASB 1045]

Interpretations:

- UIG 4 Determining whether an Arrangement contains a Lease
- UIG 5 Rights to Interests arising from Decommissioning, Restoration and Environmental Rehabilitation Funds
- UIG 7 Applying the Restatement Approach under AASB 129 Financial Reporting in Hyperinflationary Economies
- UIG 8 Scope of AASB 2
- UIG 9 Reassessment of Embedded Derivatives
- UIG 4 and UIG 9 might have impacts in future periods, subject to existing contracts being renegotiated.

Future Australian Accounting Standard requirements

The following new standards, amendments to standards or interpretations have been issued by the Australian Accounting Standards Board but are effective for future reporting periods. It is estimated that the impact of adopting these pronouncements when effective will have no material financial impact on future reporting periods.

Financial instrument disclosure

AASB 7 Financial Instruments: Disclosures is effective for reporting periods beginning on or after 1 January 2007 (the 2007-08 financial year) and amends the disclosure requirements for financial instruments. In general AASB 7 requires greater disclosure than that presently. Associated with the introduction of AASB 7 a number of accounting standards were amended to reference the new standard or remove the present disclosure requirements through 2005-10 Amendments to Australian Accounting Standards [AASB 132, AASB 101, AASB 114, AASB 117, AASB 133, AASB 139, AASB 1, AASB 4, AASB 1023 & AASB 1038]. These changes have no financial impact but will affect the disclosure presented in future financial reports.

Other

The following standards and interpretations have been issued but are not applicable to the operations of the NBA.

- AASB 1049 Financial Reporting of General Government Sectors by Governments
- UIG 10 Interim Financial Reporting and Impairment

1.5 Revenue

Revenues from Government

Amounts appropriated for Departmental outputs appropriations for the year (less any current year additions and reductions) are recognised as revenue, except for certain amounts that relate to activities that are reciprocal in nature, in which case, revenue is recognised only when it has been earned.

Appropriations receivable are recognised at their nominal amounts.

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

Other Types of Revenue

Revenue from the sale of goods is recognised when:

- The risks and rewards of ownership have been transferred to the buyer;
- The seller retains no managerial involvement nor effective control over the goods;
- The revenue and transaction costs incurred can be reliably measured; and
- It is probable that the economic benefits associated with the transaction will flow to the entity.

Revenue from rendering of services is recognised by reference to the stage of completion of contracts at the reporting date. The revenue is recognised when:

- The amount of revenue, stage of completion and transaction costs incurred can be reliably measured; and
- The probable economic benefits with the transaction will flow to the entity.

Receivables for goods and services which have 30 day terms are recognised at the nominal amounts due less any provision for bad and doubtful debts. Collectability of debts is reviewed at balance date. Provisions are made when collectability of the debt is no longer probable.

Section 31 Revenue

Section 83 of the Constitution, prescribes that monies are not to be drawn down from the Treasury, except under an appropriation by law. Further, under Section 31 of the *Financial Management and Accountability Act 1997*, an agreement may be made with the Finance Minister which specifies the type of receipts that, are not included in the Appropriation Acts, but may be deemed to be appropriated.

The NBA receives monies from a number of sources, other than appropriations, and those revenues that are stipulated within the *National Blood Authority Act 2003*. The NBA has a Net Appropriation instrument that allows the NBA to retain and spend these receipts.

1.6 Gains

Other Resources Received Free of Charge

Resources received free of charge are recognised as gains when and only when a fair value can be reliably determined and the resources would have been purchased if they had not been donated. Use of those resources is recognised as an expense.

Contributions of assets at no cost of acquisition or for nominal consideration are recognised as revenue at their fair value when the asset qualifies for recognition, unless received from another government agency as a consequence of a restructuring of administrative arrangements.

Sale of Assets

Gains from the disposal of non-current assets are recognised when control of the assets has passed to the buyer.

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

1.7 Transactions with the Government as Owner

Restructuring of Administrative Arrangements

Net assets received from or relinquished to another Australian Government agency or NBA under a restructuring of administrative arrangements are adjusted at their book value directly against contributed equity.

Equity injections

Amounts appropriated which are designated as 'equity injections' for a year (less any formal reductions) are recognised directly in Contributed Equity in that year.

1.8 Employee Benefits

Liabilities for services rendered by employees are recognised at the reporting date to the extent that they have not been settled.

Liabilities for 'short-term employee benefits' (as defined in AASB 119) and termination benefits due within twelve months of balance date are measured at their nominal amounts.

The nominal amount is calculated with regard to the rates expected to be paid on settlement of the liability.

All other employee benefit liabilities are measured as the present value of the estimated future cash outflows to be made in respect of services provided by employees up to the reporting date.

Leave

The liability for employee entitlements includes provision for annual leave and long service leave. No provision has been made for sick leave as all sick leave is non-vesting and the average sick leave taken in future years by employees of the NBA is estimated to be less than the annual entitlement for sick leave.

The leave liabilities are calculated on the basis of employees' remuneration, including the NBA's employer superannuation contribution rates to the extent that the leave is likely to be taken during service rather than paid out on termination.

The liability for long service leave is recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at 30 June 2007. In determining the present value of the liability, the NBA has taken into account attrition rates and pay increases through promotion and inflation.

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

Superannuation

Staff of the NBA are members of the Commonwealth Superannuation Scheme (CSS), the Public Sector Superannuation Scheme (PSS), the PSS accumulation plan (PSSap), or the Australian Government Employee Superannuation Trust. The CSS and PSS are defined benefit schemes for the Commonwealth. The PSSap is a defined contribution scheme. From 1 July 2005, new employees are eligible to join the PSSap scheme.

The NBA makes employer contributions to the Employee Superannuation Scheme at rates determined by an actuary to be sufficient to meet the cost to the Government of the superannuation entitlements of the NBA's employees.

The liability for their defined benefits is recognised in the financial statements of the Australian Government and is settled by the Australian Government in due course.

1.9 Leases

A distinction is made between finance leases and operating leases. Finance leases effectively transfer from the lessor to the lessee substantially all the risks and benefits incidental to ownership of leased non-current assets. An operating lease is a lease that is not a finance lease. In operating leases, the lessor effectively retains substantially all such risks and benefits. The NBA has no finance leases as at 30 June 2007.

Operating lease payments are expensed on a straight line basis which is representative of the pattern of benefits derived from the leased assets.

1.10 Cash

Cash means notes and coins held and any deposits held at call with a bank or financial institution. Cash is recognised at its nominal amount.

1.11 Financial Risk Management

The NBA's activities expose it to normal commercial financial risk. As a result of the nature of the NBA's business and internal Australian Government policies, dealing with the management of financial risk, the NBA's exposure to market, credit, liquidity and cash flow and fair value interest rate risk is considered to be low.

1.12 Other Financial Instruments

Trade Creditors

Trade creditors and accruals are recognised at their nominal amounts, being the amounts at which the liabilities will be settled. Liabilities are recognised to the extent that the goods or services have been received (and irrespective of having been invoiced).

Contingent Liabilities and Contingent Assets

Contingent liabilities or assets are not recognised in the Balance Sheet but are discussed in the relevant schedules and notes. They may arise from uncertainty as to the existence of a liability or asset, or represent an existing liability or asset in respect of which settlement is not probable or the amount cannot be reliably measured. Remote contingencies are part of this disclosure. Where settlement becomes probable, a liability or asset is recognised. A liability or asset is recognised when its existence is confirmed by a future event, settlement becomes probable or reliable measurement becomes possible.

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

1.13 Impairment of Financial Assets

Financial assets are assessed for impairment at each balance date. As at 1 July 2006 and 30 June 2007 there were no impairments of Financial Assets for the NBA.

For receivables, amounts are recognised and carried at original invoice amount less a provision for doubtful debts based on an estimate made when collection of the full amount was no longer probable. Bad debts were written off as incurred.

1.14 Acquisition of Assets

Assets are recorded at cost on acquisition, except as stated below. The cost of acquisition includes the fair value of assets transferred in exchange and liabilities undertaken. Financial assets are initially measured at their fair value plus transaction costs where appropriate.

Assets acquired at no cost, or for nominal consideration, are initially recognised as assets and revenues at their fair value at the date of acquisition, unless acquired as a consequence of restructuring of administrative arrangements. In the latter case, assets are initially recognised as contributions by owners at the amounts at which they were recognised in the transferor Agency's accounts immediately prior to the restructuring.

1.15 Property, Plant and Equipment (PP&E)

Asset Recognition Threshold

Purchases of property, plant and equipment are recognised initially at cost in the Balance Sheet, except for purchases costing less than the thresholds listed below for each class of asset, which are expensed in the year of acquisition (other than where they form part of a group of similar items which are significant in total).

Asset class	Recognition Threshold
Infrastructure, Plant and Equipment	\$2,000
Leasehold improvements	\$10,000
Software	\$5,000

The initial cost of an asset includes an estimate of the cost of dismantling and removing the item and restoring the site on which it is located. This is particularly relevant to 'make good' provisions in property leases taken up by the NBA where there exists an obligation to restore the property to its original condition. These costs are included in the value of the NBA's leasehold improvements with a corresponding provision for the 'make good' taken up.

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

Revaluations

Basis

All valuations are conducted by an independent qualified valuer and were undertaken by the Australian Valuation Office at 30 June 2007.

Fair values for each class of asset are determined as shown below.

Asset class	Fair value measured at:
Leasehold improvements	Depreciated replacement cost
Infrastructure, plant & equipment	Market selling price

Following initial recognition at cost, property, plant and equipment are carried at fair value less accumulated depreciation and accumulated impairment losses. Valuations are conducted with sufficient frequency to ensure that the carrying amounts of assets do not materially differ with the assets' fair values as at the reporting date. The regularity of independent valuations depends upon the volatility of movements in market values for the relevant assets.

Revaluation adjustments are made on a class basis. Any revaluation increment is credited to equity under the heading of asset revaluation reserve except to the extent that it reverses a previous revaluation decrement of the same asset class that was previously recognised through profit and loss. Revaluation decrements for a class of assets are recognised directly through profit and loss except to the extent that they reverse a previous revaluation increment for that class.

Any accumulated depreciation as at the revaluation date is eliminated against the gross carrying amount of the asset and the asset restated to the revalued amount.

Frequency

Infrastructure, plant and equipment and Leasehold improvements will be revalued every year in accordance with the Finance Ministers Orders.

Depreciation

Depreciable plant and equipment assets are written-off to their estimated residual values over their estimated useful lives to the NBA using, in all cases, the straight-line method of depreciation. Leasehold improvements are depreciated on a straight-line basis over the lesser of the estimated useful life of the improvements or the unexpired period of the lease.

Depreciation rates (useful lives) and methods are reviewed at each reporting date and necessary adjustments are recognised in the current, or current and future reporting periods, as appropriate. Residual values are re-estimated for a change in prices only when assets are revalued. Depreciation rates applying to each class of depreciable asset are based on the following useful lives:

	2006-07	2005-06
Infrastructure, Plant and Equipment	3 to 7 years	3 to 7 years
Leasehold improvements	Lease term	Lease term

The aggregate amount of depreciation allocated for each class of asset during the reporting period is disclosed in Note 4C.

6: Appendices

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

1.16 Impairment of Non-Current Assets

All assets were assessed for impairment at 30 June 2007. Where indications of impairment exist, the asset's recoverable amount is estimated and an impairment adjustment made if the asset's recoverable amount is less than its carrying amount.

The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use. Value in use is the present value of the future cash flows expected to be derived from the asset. Where the future economic benefit of an asset is not primarily dependent on the asset's ability to generate future cash flows, and the asset would be replaced if the NBA were deprived of the asset, its value in use is taken to be its depreciated replacement cost.

No indicators of impairment were found for assets at fair value.

1.17 Intangibles

The NBA's intangibles comprise internally developed and purchased software for internal use. These assets are carried at cost.

Software is amortised on a straight-line basis over its anticipated useful life. The useful lives of the NBA's software are:

	2006-07	2005-06
Purchased software	3 years	3 years
Internally developed software	3 years	3 years

All software assets are assessed for impairment at each balance date. As at 30 June 2007 there were no impairments of intangibles for the NBA.

1.18 Taxation

The NBA is exempt from all forms of taxation except fringe benefits tax (FBT) and the goods and services tax (GST).

Revenue, expenses and assets are recognised net of GST, except;

- where the amount of the GST incurred is not recoverable from the Australian Taxation Office; and
- for receivables and payables.

1.19 Foreign Currency

Transactions denominated in a foreign currency are converted at the exchange rate at the date of the transaction. Foreign currency receivables and payables are translated at the exchange rates current as at balance date where material. Associated currency gains and losses are not material.

1.20 Insurance

The NBA is insured for risks through the Government's insurable risk managed fund, called 'Comcover'. Workers compensation is insured through the Government's Comcare Australia.

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

1.21 Reporting of Administered Activities

Administered revenues, expenses, assets, liabilities and cash flows are disclosed in the Schedule of Administered Items and related Notes.

Except where otherwise stated below, administered items are accounted for on the same basis and using the same policies as for Departmental items, including the application of Australian Accounting Standards.

Administered Cash Transfers to and from Official Public Account

Revenue collected by the NBA for use by the Government rather than the NBA is Administered Revenue. Collections are transferred to the Official Public Account (OPA) maintained by the Department of Finance. Conversely, cash is drawn from the OPA to make payments under Parliamentary appropriation on behalf of Government. These transfers to and from the OPA are adjustments to the administered cash held by the NBA on behalf of the Government and reported as such in the Administered Cash Flow in the Schedule of Administered Items and in the Administered Reconciliation Table in Note 19. Thus the Schedule of Administered Items largely reflects the Government's transactions, through the NBA, with parties outside the Government.

Revenue

All administered revenues are revenues relating to the core operating activities performed by the NBA on behalf of the Australian Government.

Administered fee revenue is recognised when access occurs. Collectability of debts is reviewed at balance date. Allowances are made when collection of the debt is judged to be less rather than more likely.

Grants

Grant liabilities are recognised to the extent that (i) the services required to be performed by the grantee have been performed or (ii) the grant eligibility criteria have been satisfied, but payments due have not been made. A commitment is recorded when the Government enters into an agreement to make these grants but services have not been performed or criteria satisfied.

Inventories of Blood and Blood Related Products

The Australian Government controls the National Reserve of Blood and Blood Related Products (the "Reserve"). There are three significant input costs to the Reserve:

- Collection costs of raw plasma product provided by the Australian Red Cross Blood Service (ARCBS);
- Purchase costs paid to CSL Ltd for the plasma product; and
- Purchase costs paid to other suppliers for blood related products.

Since the establishment of the NBA, processes have been put in place that allow for the collection of data to enable measurement of these costs. A costing methodology has been agreed and will be reviewed annually to ensure reliability and appropriateness.

The NBA negotiated and implemented new arrangements with CSL Ltd in December 2004. These arrangements formalised the control of an inventory buffer, known as Post Payment Inventory of Blood Products ("POPI"), held at CSL Ltd for use by governments.

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

The Australian Government now controls POPI and from 2004-05 is disclosed in the financial statements for the NBA. There are two significant input costs to POPI:

- Collection costs of raw plasma product provided by the ARCBS; and
- Purchase costs paid to CSL Ltd for the plasma product.

The NBA negotiated and implemented new arrangements with the Australian Red Cross Blood Service in August 2006. These arrangements formalised the control of the inventory held by ARCBS on behalf of the NBA for distribution to approved recipients.

The Australian Government now controls ARCBS Inventory and from 2006-07 is disclosed in the financial statements for the NBA. There are three significant input costs to ARCBS Inventory:

- Collection costs of raw plasma product provided by the ARCBS; and
- Purchase costs paid to CSL Ltd for the plasma product.
- Purchase costs paid to other suppliers for blood related products.

Inventories held for distribution are measured at cost per the requirements of Accounting Standard AASB 102. A costing methodology has been agreed and will be reviewed annually to ensure reliability and appropriateness.

Movements in the Reserve, POPI and ARCBS are funded from the Australian Government and State and Territories as per the National Blood Agreement.

National Managed Fund

The National Managed Fund was established to manage the liability risks of the Australian Red Cross Blood Service in relation to the provision of blood and blood products. The National Managed Fund was reported in 2003-04 by the Department of Health and Ageing under “Services for Other Governments and Non-Departmental Bodies Special Account”. The NBA now manages this fund on behalf of the Australian Government and States and Territories. To facilitate the transfer of the fund to the NBA a special account under Section 20 of the *Financial Management and Accountability (FMA) Act 1997* was established, and this fund was transferred to the NBA for reporting.

The Fund came into effect on 1 July 2000 and to date, no claims have been made against the fund. The balance of the fund as at 30 June 2007 is \$41,686,565. Refer to Note 23.

Indemnities

The maximum amounts payable under the indemnities given is disclosed in the Schedule of Administered Items – Contingencies. At the time of completion of the financial statements, there was no reason to believe that the indemnities would be called upon, and no recognition of any liability was therefore required.

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

NOTE 2 Events after the Balance Sheet Date

There were no significant events occurring after 30 June 2007.

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

	2007 \$'000	2006 \$'000
NOTE 3 Income		
Revenues		
<u>Note 3A - Revenues from Government</u>		
Appropriations for outputs	6 065	4 532
Total revenues from government	6 065	4 532
<u>Note 3B - Sale of goods and rendering of services</u>		
Rendering of services	4 064	3 570
Total sales of goods and services	4 064	3 570
Rendering of services to:		
Related entities	347	821
External entities	3 717	2 749
Total rendering of services	4 064	3 570
Gains		
<u>Note 3C - Other gains</u>		
Resources received free of charge	96	91

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

	2007	2006
	\$'000	\$'000
NOTE 4 Operating Expenses		
<u>Note 4A - Employee benefits</u>		
Wages and salaries	3 456	2 997
Superannuation	622	570
Leave and other entitlements	768	591
Other employee expenses	866	701
Total employee expenses	5 712	4 859
<u>Note 4B - Suppliers</u>		
Provision of goods - external entities	151	133
Rendering of services - related entities	183	218
Rendering of services - external entities	2 197	1 712
Operating lease rentals - minimum lease payments	332	291
Workers compensation premiums	78	41
Total supplier expenses	2 941	2 395
<u>Note 4C - Depreciation and amortisation</u>		
The aggregate amounts of depreciation or amortisation expensed during the reporting period for each class of depreciable asset are as follows:		
<i>(i) Depreciation</i>		
Infrastructure, plant and equipment	99	81
Leasehold improvements	83	102
Total Depreciation	182	183
<i>(ii) Amortisation</i>		
Intangibles - Computer software	102	102
Total depreciation and amortisation	284	285
No depreciation or amortisation was allocated to the carrying amounts of other assets		
<u>Note 4D - Write-down and impairment of assets</u>		
Non-financial assets:		
Write-off non-financial assets	75	3
Revaluation decrements - non-financial assets		
Leasehold improvements	31	80
Infrastructure, plant and equipment	5	-
Total write-down and impairment of assets	111	83
<u>Note 4E - Losses from asset sales</u>		
Infrastructure, plant and equipment		
Proceeds from disposals	(18)	-
Net book value of assets disposed	29	6
Net loss from disposal of infrastructure, plant and equipment	11	6

6: Appendices

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

	2007 \$'000	2006 \$'000
NOTE 5 Financial Assets		
<u>Note 5A - Cash</u>		
Cash at bank - Special Account	53	61
Total cash	<u>53</u>	<u>61</u>
 <u>Note 5B - Trade and other receivables</u>		
Goods and services	240	-
less allowance for doubtful debts	-	-
	<u>240</u>	-
All debt is current and therefore no provision is required.		
 Goods and Services Tax (GST) receivable from ATO	103	55
Appropriation receivable	317	406
Appropriation receivable - Special Account	<u>8 582</u>	<u>7 294</u>
Total receivables (net)	<u>9 242</u>	<u>7 755</u>
 Receivables is represented by:		
Current	9 242	7 349
Non-current	-	-
Total receivables (net)	<u>9 242</u>	<u>7 349</u>
 All receivables are with entities external to the entity. Credit terms are net 30 days (2005/06: 30 days).		
 Receivables (gross) are aged as follows:		
Not overdue	8 899	7 294
Overdue by less than 30 days	<u>343</u>	<u>55</u>
Total receivables (gross)	<u>9 242</u>	<u>7 349</u>

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

	2007 \$'000	2006 \$'000
NOTE 6 Non-Financial Assets		
<u>Note 6A - Leasehold improvements</u>		
- at fair value	228	324
- accumulated depreciation	-	-
Total leasehold improvements (non-current)	228	324
<u>Note 6B - Infrastructure, plant and equipment</u>		
- gross carrying value (at fair value)	241	317
- accumulated depreciation	(1)	-
Total infrastructure, plant and equipment (non-current)	240	317
<u>Note 6C - Intangible assets</u>		
Computer software - at cost		
Internally developed - in use	39	39
Purchased - in use	204	288
Total computer software	243	327
Accumulated amortisation - internally developed	(39)	(32)
Accumulated amortisation - purchased	(165)	(175)
Total accumulated amortisation	(204)	(207)
Computer software - internally developed - in progress	766	-
Total intangibles (non-current)	805	120
<u>Note 6D - Other non-financial assets</u>		
Prepayments	17	8

All other non-financial assets are current assets.

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

Note 6E - Analysis of property, plant and equipment and intangibles

Table A - Reconciliation of the opening and closing balances of property, plant and equipment, and intangibles (2006-07)

Item	Leasehold improvements	Infrastructure plant and equipment	Intangibles - Computer software internally developed	Intangibles - Computer software purchased
	\$'000	\$'000	\$'000	\$'000
As at 1 July 2006				
Gross book value	324	317	39	288
Accumulated depreciation/amortisation	-	-	(32)	(175)
Opening Net book value	324	317	7	113
Additions:				
By purchase/internally developed	18	136	-	22
Net revaluation increment/(decrement)	(31)	(11)	-	-
Depreciation/amortisation expense	(83)	(99)	(7)	(95)
Disposals:				
Other disposals	-	(103)	-	(1)
Net book value 30 June 2007	228	240	-	39

Net book value as of 30 June 2007 represented by:				
Gross book value	228	241	39	204
Accumulated depreciation/amortisation	-	(1)	(39)	(165)
Closing Net book value	228	240	-	39
Internally developed software - in progress	-	-	766	-
Total of all assets	228	240	766	39

Table B - Reconciliation of the opening and closing balances of property, plant and equipment, and intangibles (2005-06)

Item	Leasehold improvements	Infrastructure plant and equipment	Intangibles - Computer software internally developed	Intangibles - Computer software purchased
	\$'000	\$'000	\$'000	\$'000
As at 1 July 2005				
Gross book value	331	331	39	251
Accumulated depreciation/amortisation	(2)	(4)	(19)	(87)
Opening Net book value	329	327	20	164
Additions:				
By purchase/internally developed	179	88	-	37
Net revaluation increment/(decrement)	(82)	(11)	-	-
Depreciation/amortisation expense	(102)	(81)	(13)	(88)
Disposals:				
Other disposals	-	(6)	-	-
Net book value 30 June 2006	324	317	7	113

Net book value as of 30 June 2006 represented by:				
Gross book value	324	317	39	288
Accumulated depreciation/amortisation	-	-	(32)	(175)
Closing Net book value	324	317	7	113

6: Appendices

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

	2007	2006
	\$'000	\$'000
NOTE 7 Payables		
<u>Note 7A - Suppliers</u>		
Suppliers	659	498
Total supplier payables	659	498
All supplier payables are current liabilities.		
Supplier payables are represented by:		
Current	659	498
Total supplier payables	659	498
 <u>Note 7B - Other payables</u>		
Unearned revenue from States and Territories	1 302	1 094
Unearned revenue from outputs	1 694	1 694
Unearned revenue - S31 receipts	695	695
Total other payables	3 691	3 483
All other payables are current liabilities.		
 NOTE 8 Provisions		
<u>Note 8 - Employee provisions</u>		
Salaries and wages	39	42
Leave	930	862
Total employee provisions	969	904
Employee provisions are represented by:		
Current	690	786
Non-current	279	118
Total employee provisions	969	904

6: Appendices

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

	2007 \$'000	2006 \$'000
NOTE 9 Cash Flow Reconciliation		
Reconciliation of cash and cash equivalents per Balance Sheet to Cash Flow Statement		
Cash at year end as per Cash Flow Statement	53	61
Cash at year end as per Balance Sheet	53	61
Reconciliation of operating result to net cash from operating activities:		
Operating result	1 166	565
Depreciation/amortisation	284	285
Revaluation reserve increment	(6)	(13)
Revenue from sale of assets	-	-
Changes in assets and liabilities:		
Decrease/(increase) in receivables	(227)	196
Decrease/(increase) in non-financial assets	154	147
Increase/(decrease) in employee liabilities	69	(132)
Increase/(decrease) in supplier liabilities	(23)	50
Increase/(decrease) in other liabilities	208	2 108
Net cash from operating activities	1 625	3 206

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

	2007	2006
	Number	Number
NOTE 10 Remuneration of Executives		
The number of senior executives who received or were due to receive total remuneration of \$130,000 or more:		
\$130 000 to 144 999	1	-
\$145 000 to 159 999	-	1
\$160 000 to 174 999	1	-
\$190 000 to \$204 999	1	1
\$280 000 to \$294 999	1	1
	<hr/> 4 <hr/>	<hr/> 3 <hr/>

The aggregate amount of total monies expended and accrued by the organisation relevant to the employment of senior executives shown above.

	\$	\$
	799 496	617 923

This includes salaries, employer superannuation contributions to CSS, PSS and PSSap, accrued leave and performance bonuses.

The aggregate amount of separation and redundancy/termination benefit payments during the year to executives shown above.

-	-
---	---

In 2006-07 some executives were employed for part of the year due to staff leaving.

	2007	2006
	\$'000	\$'000
NOTE 11 Remuneration of Auditors		
Financial statement audit services are provided free of charge to the NBA.		
The fair value of the services provided was:	<hr/> 96 <hr/>	<hr/> 91 <hr/>
	<hr/> 96 <hr/>	<hr/> 91 <hr/>

No other services were provided by the Auditor-General.

	2007	2006
	Number	Number
NOTE 12 Average Staffing Levels		
The average staffing levels for the NBA at balance date were:	<hr/> 50 <hr/>	<hr/> 49 <hr/>

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

NOTE 13 Contingent Liabilities and Assets

Quantifiable Contingencies

There are no contingent liabilities or contingent assets in this reporting period.

Unquantifiable Contingencies

There are no contingent liabilities in this reporting period.

The National Blood Authority office accommodation sustained water damage in February 2007 following a hail storm that affected many buildings in Canberra city. The initial insurance claim has been submitted to Comcover for approval and subsequent payment. To date the NBA has been advised that approximately \$213,000 has been validated and this has been accrued in the 2006-07 statements. The NBA is still waiting for replacement office furniture to be delivered and it expected that this will be available in August 2007 at which time the claim will be further assessed by Comcover.

Remote Contingencies

The Australian Government has indemnified the lessor of the National Blood Authority's premises for negligent acts committed by the National Blood Authority up to the value of \$1,000,000.

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

NOTE 14 Financial Instruments

(a) Terms, conditions and accounting policies

Financial Instrument	Notes	Accounting Policies and Methods (including recognition criteria and measurement basis)	Nature of underlying instrument (including significant terms and conditions affecting the amount, timing and certainty of cash flow)
Financial Assets		Financial assets are recognised when control over future economic benefits is established and the amount of the benefit can be reliably measured.	
Cash	5A	Deposits are recognised at their nominal amounts.	Monies in the Authority's bank accounts were from States and Territories and the Australian Government. Government contributions were swept to the Official Public Account and held as a special account.
Receivable for goods and services	5B	These receivables are recognised at the nominal amounts due less any provision for bad or doubtful debts. Collectability of debts is reviewed at balance date. Provisions are made when collection of debt is judged to be less rather than more likely.	All receivables are with States and Territories and the Australian Government. Credit terms are net 30 days.
Appropriation receivable - Special Account	5B	These receivables are recognised at the nominal amounts.	Amounts appropriated by Parliament in the current year which are available to be drawn down by the Authority.
Financial Liabilities		Financial liabilities are recognised when a present obligation to another party is entered into and the amount of the liability can be reliably measured.	
Trade and other creditors	7A	Creditors and accruals are recognised at their nominal amounts, being the amounts at which the liabilities will be settled. Liabilities are recognised to the extent the goods and services have been received (and irrespective of having been invoiced).	

**NATIONAL BLOOD AUTHORITY
STATEMENT OF CHANGES IN EQUITY**
for the year ended 30 June 2007

NOTE 14 Financial Instruments (continued)
Note 14A Interest rate risk

Financial instrument	Notes	Floating interest rate		Fixed interest rate						Non interest bearing		Total		Weighted average effective interest rate		
		2007 \$'000	2006 \$'000	1 year or less 2007 \$'000	2006 \$'000	1-5 years 2007 \$'000	2006 \$'000	> 5 years 2007 \$'000	2006 \$'000	2007 \$'000	2006 \$'000	2007 \$'000	2006 \$'000	2007 \$'000	2007 %	2006 %
Financial assets																
Cash at bank	5A	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	53	61	53	61	n/a	n/a	n/a
Receivables for goods and services	5B	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	343	55	343	55	n/a	n/a	n/a
Appropriation receivable - Special Account	5B	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	8 582	7 294	8 582	7 294	n/a	n/a	n/a
Total financial assets (recognised)										8 978	7 410	8 978	7 410			
Total Assets												10 585	8 595			
Financial liabilities																
Trade and other creditors	7A	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	659	498	659	498	n/a	n/a	n/a
Total financial liabilities (recognised)										659	498	659	498			
Total Liabilities												5 319	4 885			

6: Appendices

**NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS**
for the year ended 30 June 2007

NOTE 14 Financial Instruments (continued)
Note 14B Fair value of financial assets and liabilities

	Note	2007		2006	
		Total carrying amount	Aggregate fair value \$'000	Total carrying amount \$'000	Aggregate fair value \$'000
Departmental Financial assets					
Cash at bank	5A	53	53	61	61
Receivables for goods and services	5B	343	343	55	55
Appropriation receivable - Special account	5B	8 582	8 582	7 294	7 294
Total financial assets		8 978	8 978	7 410	7 410
Financial liabilities (recognised)					
Trade and other creditors	7A	659	659	498	498
Total financial liabilities (recognised)		659	659	498	498

Financial assets

The fair values of all monetary financial assets approximate their carrying amounts.

Financial liabilities

The fair values of all monetary financial liabilities are approximated by their carrying amounts.

Credit risk exposure

The NBA's maximum exposures to credit risk at reporting date in relation to each class of recognised financial assets is the carrying amount of those assets as indicated in the Balance Sheet.

The NBA has no significant exposures to any concentrations of credit risk.

All figures for credit risk referred to do not take into account the value of any collateral or other security

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

	2007 \$'000	2006 \$'000
NOTE 15		
Income Administered on Behalf of Government		
Revenue		
Non-taxation revenue	223 957	213 875
Other revenue	22 990	-
State and Territory contributions	-	3 200
Contributions of assets		
Other	<u>246 947</u>	<u>217 075</u>

Total income administered on behalf of Government

	\$'000	\$'000
NOTE 16		
Expenses Administered on Behalf of Government		

Grants

Private sector - non-profit organisations	305 770	299 296
---	---------	---------

The nature of the grant is a Deed for the provision of services relating to blood and blood related products.

Suppliers

Provision of goods and services - external entities	303 080	266 843
---	---------	---------

Total expenses administered on behalf of Government

<u>608 850</u>	<u>566 139</u>
----------------	----------------

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

	2007 \$'000	2006 \$'000
NOTE 17 Assets Administered on Behalf of Government		
Financial assets		
<u>Note 17A - Cash</u>	-	-
Administered bank account	-	-
	515	2 080
<u>Note 17B - Receivables</u>	-	-
Goods and services receivable	515	2 080
less provision for doubtful debts	7 860	10 007
	8 375	12 087
Goods and Services Tax receivable from ATO		
Total receivables (net)	8 375	12 087
Receivables is represented by:	-	-
Current		
Non-current	8 375	12 087
Total receivables (net)	8 375	12 087
<i>Receivables (gross) are aged as follows:</i>	8 375	12 087
Not overdue		
Total receivables (gross)		
Non-financial assets		
	31 035	27 615
<u>Note 17C - Inventory</u>	34 214	21 451
National Reserve - inventory held for distribution	65 249	49 066
Other inventory held for distribution		
Total inventory	10 071	-
<u>Note 17D - Other non-financial assets</u>	10 071	-
Prepayments		
Total other	83 695	61 153
Total assets administered on behalf of Government		
NOTE 18 Liabilities Administered on Behalf of Government		
	28 331	54 689
<u>Note 18A - Suppliers</u>		
Suppliers	36 808	24 687
<u>Note 18B - Unearned income</u>	206	206
Unearned income - States and Territories	37 014	24 893
Unearned income - other		
Total payables	65 345	79 582
Total liabilities administered on behalf of Government		

All liabilities are expected to be settled within 12 months of balance date.

6: Appendices

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

2007 2006
\$'000 \$'000

NOTE 19 Administered Reconciliation Table

Opening administered assets less administered liabilities at 1 July	(18 429)	19 412
<i>Plus</i> Administered revenues	246 947	217 075
<i>Less</i> Administered expenses	(608 850)	(566 139)
	(380 332)	(329 652)
Administered transfers to/from Government		
Transfers from OPA		
Appropriation transfers from OPA - Special Account	699 670	587 145
Transfers to OPA		
Appropriation transfers to OPA - Special Account	(300 988)	(275 922)
	398 682	311 223
Closing Administered assets less liabilities	18 350	(18 429)

NOTE 20 Administered Contingent Liabilities and Assets

Unquantifiable Administered Contingent Liabilities

Under certain conditions the Australian Government and the States/Territories jointly provide indemnity for the Australian Red Cross Blood Service through a cost sharing arrangement for claims, both current and potential, regarding personal injury and loss of damage suffered by a recipient of certain blood products. The Australian Government's share of any liability is limited to sixty three percent of any agreed net cost.

Under previous agreements, the Australian Government has indemnified CSL Limited for certain existing and potential claims made for personal injury, loss or damage suffered through therapeutic and diagnostic use of certain products manufactured by CSL Limited. These indemnities survive the expiry of the agreements. No similar indemnities have been given to CSL Limited under the new existing agreements.

The Deed of Agreement between the Australian Red Cross Society (ARCS) and the National Blood Authority (NBA) in relation to the operation of the Australian Red Cross Blood Society (ARCBS) includes certain indemnities and a limit of liability in favour of ARCS. These cover a defined set of potential business, product and employee risks and liabilities arising from the operations of ARCBS. The indemnities and limitation of liability only operate in the event of the expiry and non-renewal, or the earlier termination, of the Deed of Agreement, and only within a defined scope. They are also subject to appropriate limitations and conditions including in relation to mitigation, contributory fault, and the process of handling relevant claims.

Under the terms of a current supply agreement, the Australian Government has an obligation to seek to reach agreement with CSL Limited, within certain parameters, on payments to be made to CSL Limited in recognition of the unavoidable and unrecoverable fixed costs incurred by CSL Limited in the production and supply of low volumes of certain products under that agreement. The amount of any payment cannot be quantified until agreement is reached.

Unquantifiable Administered Contingent Assets

There are no unquantifiable administered contingent assets in this reporting period.

Remote Material Administered Contingencies

There are no remote material administered contingent liabilities or contingent assets in this reporting period.

6: Appendices

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

NOTE 21 Administered Financial Instruments			
<i>(a) Terms, conditions and accounting policies</i>			
Financial Instrument	Notes	Accounting Policies and Methods (including recognition criteria and measurement basis)	Nature of underlying instrument (including significant terms and conditions affecting the amount, timing and certainty of cash flow)
Financial Assets		Financial assets are recognised when control over future economic benefits is established and the amount of the benefit can be reliably measured.	
Cash	17A	Deposits are recognised at their nominal amounts.	Monies in the Authority's bank accounts were swept nightly into the Official Public Account and held as a Special account.
Receivable for goods and services	17B	These receivables are recognised at the nominal amounts due less any provision for bad or doubtful debts. Collectability of debts is reviewed at balance date. Provisions are made when collection of debt is judged to be less rather than more likely.	All receivables are with States and Territories and the Australian Government. Credit terms are net 30 days.
Financial Liabilities		Financial liabilities are recognised when a present obligation to another party is entered into and the amount of the liability can be reliably measured.	
Trade and other creditors	18A	Creditors and accruals are recognised at their nominal amounts, being the amounts at which the liabilities will be settled. Liabilities are recognised to the extent the goods and services have been received (and irrespective of having been invoiced).	

6: Appendices

NATIONAL BLOOD AUTHORITY
 NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
 for the year ended 30 June 2007

NOTE 21 Administered Financial Instruments															
Note 21A - Interest rate risk															
Financial instrument	Notes	Floating interest rate		Fixed interest rate						Non interest bearing		Total		Weighted average effective interest rate	
		2007 \$'000	2006 \$'000	1 year or less 2007 \$'000	2006 \$'000	1 - 5 years 2007 \$'000	2006 \$'000	> 5 years 2007 \$'000	2006 \$'000	2007 \$'000	2006 \$'000	2007 \$'000	2006 \$'000	2007 %	2006 %
Financial assets															
Cash	17A	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	-	-	n/a	n/a
Receivable for goods and services	17B	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	8,375	12,087	8,375	12,087	n/a	n/a
Total financial assets (recognised)		-	-	-	-	-	-	-	-	8,375	12,087	8,375	12,087		
Total Assets Administered on Behalf of the Government												83,695	61,153		
Financial liabilities															
Trade and other creditors	18A	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	28,331	54,689	28,331	54,689	n/a	n/a
Total financial liabilities (recognised)		-	-	-	-	-	-	-	-	28,331	54,689	28,331	54,689		
Total Liabilities Administered on Behalf of the Government												66,345	79,992		

**NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS**
for the year ended 30 June 2007

NOTE 21 Administered financial instruments (continued)

Note 21B Fair value of financial assets and liabilities

	Note	2007		2006	
		Total carrying amount \$'000	Aggregate fair value \$'000	Total carrying amount \$'000	Aggregate fair value \$'000
Administered					
Financial assets					
Cash	17A	-	-	-	-
Receivable for goods and services	17B	8 375	8 375	12 087	12 087
Total financial assets		8 375	8 375	12 087	12 087
Financial liabilities (recognised)					
Trade and other creditors	18A	28 331	28 331	54 689	54 689
Total financial liabilities (recognised)		28 331	28 331	54 689	54 689

NATIONAL BLOOD AUTHORITY
 NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
 for the year ended 30 June 2007

Particulars	Administered Expenses				Departmental Outputs				Total	
	Outcome 1									
	2007	2006	2007	2006	2007	2006	2007	2006	2007	2006
Year ended 30 June	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$
Balance carried from previous period	158 464 610	102 768 423	7 354 950	4 488 854	165 819 560	107 257 282				
Reductions of appropriations (prior years)	-	-	-	-	-	-	-	-	-	-
Adjusted balance carried from previous period	158 464 610	102 768 423	7 354 950	4 488 854	165 819 560	107 257 282				
Appropriation Act (No. 1)	5 933 000	-	6 065 000	6 226 000	11 998 000	6 226 000				
Appropriation Act (No. 3)	-	3 091 000	-	-	-	-				3 091 000
Departmental adjustments by the Finance Minister (Appropriation Acts)	-	-	-	-	-	-				-
Advance to the Finance Minister	-	-	-	-	-	-				-
Adjustment of appropriation on change of entity function (FIMAA s.32)	-	-	-	-	-	-				-
Refunds credited (FIMAA s.30)	-	-	-	-	-	-				-
Appropriation reduced by section 9 determinations (current year)	-	-	-	-	-	-				-
Sub Total Annual Appropriations	5 933 000	3 091 000	6 065 000	6 226 000	11 998 000	9 317 000				9 317 000
Appropriations to take account of recoverable GST (FIMAA s.30A)	63 344 346	52 959 787	380 733	296 839	63 725 079	53 256 626				
Annotations to net appropriations (FIMAA s. 31)	-	-	134 531	286 200	134 531	286 200				
Total appropriations available for payments	227 741 956	158 819 215	13 935 214	11 297 893	241 677 170	170 117 108				
Cash payments made during the year (GST inclusive)	699 719 199	587 174 996	9 218 653	7 817 672	708 937 852	594 992 668				
Appropriations credited to Special Accounts (excluding GST)	647 404 347	586 820 390	3 918 299	3 874 729	651 322 646	590 695 119				
Balance of Authority to Draw Cash from the CRF for Ordinary Annual Services Appropriations	175 427 104	158 464 609	8 634 860	7 354 950	184 061 964	165 819 559				
Represented by										
Cash at bank and on hand	-	-	52 862	61 227	52 862	61 227				
Appropriation receivable - Special Accounts	175 427 104	158 464 610	8 561 998	7 293 723	184 009 102	165 758 333				
Receivables - GST receivable from theATO	-	-	-	-	-	-				
Undrawn, unapplied appropriations	-	-	-	-	-	-				
Total	175 427 104	158 464 610	8 634 860	7 354 950	184 061 964	165 819 560				

6: Appendices

NATIONAL BLOOD AUTHORITY
 NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
 for the year ended 30 June 2007

Particulars	Equity		Total	
	2007	2006	2007	2006
Note 22 Appropriations (continued)				
Note 22B - Acquittal of Authority to Draw Cash from the Consolidated Revenue Fund for other than Ordinary Annual Services Appropriations				
Year ended 30 June	\$	\$	\$	\$
Balance carried from previous period	406 000	-	406 000	-
Reductions of appropriations (prior years)	-	-	-	-
Adjusted balance carried from previous period	406 000	-	406 000	-
Appropriation Act (No. 2)	406 000	406 000	406 000	406 000
Appropriation Act (No.4)	-	-	-	-
Departmental Adjustments	-	-	-	-
Advance to the Finance Minister	-	-	-	-
Adjustment of appropriation on change of entity function (FMAA s.32)	-	-	-	-
Refunds credited (FMAA s.30)	-	-	-	-
Appropriation reduced by section 11 determinations (current year)	-	-	-	-
Sub Total Annual Appropriations	812 000	406 000	812 000	406 000
Appropriations to take account of recoverable GST (FMAA s.30A)	-	-	-	-
Total appropriations available for payments	812 000	406 000	812 000	406 000
Cash payments made during the year (GST inclusive)	494 864	-	494 864	-
Appropriations credited to Special Accounts (excluding GST)	-	-	-	-
Balance of Authority to Draw Cash from the CRF for other than Ordinary Annual Services Appropriations	317 136	406 000	317 136	406 000
Represented by				
Cash at bank and on hand	-	-	-	-
Appropriation receivable	317 136	406 000	317 136	406 000
Receivables - GST receivable from the ATO	-	-	-	-
Undrawn, unapplied administered appropriations	-	-	-	-
Total	317 136	406 000	317 136	406 000

6: Appendices

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

	2007 \$	2006 \$
NOTE 23 Special Accounts		
THE NATIONAL BLOOD ACCOUNT		
<p>The National Blood Authority was established on 1 July 2003 with the principal role of managing the national blood arrangements, ensuring sufficient supply and to provide a new focus on the safety and quality of blood and blood products. The funding for blood and blood products is funded from a special account established under the <i>National Blood Authority Act 2003</i>, Section 40.</p> <p>The NBA's activities contributing to its outcome are classified as either Departmental or Administered. Departmental activities involve the use of assets, liabilities, revenues and expenses controlled by the agency in its own right. Administered activities involve the management or oversight by the NBA on behalf of the Government of items controlled or incurred by the Government.</p>		
<u>National Blood Account - Departmental</u>		
Balance carried from previous year	7 351 785	4 488 854
Appropriation Act (No.1)	6 065 000	6 226 000
Appropriation Act (No.2)	494 864	-
Other receipts - States and Territory contributions	3 918 299	3 852 219
Other receipts (FMAA s31)	134 531	286 200
GST credits (FMAA s30A)	380 733	296 839
Available for payments	<u>18 345 212</u>	<u>15 150 112</u>
Payments made to employees	5 692 308	5 064 410
Payments made to suppliers	4 018 044	2 733 917
Total debits	<u>9 710 352</u>	<u>7 798 327</u>
Balance carried to next period	<u>8 634 860</u>	<u>7 351 785</u>
Represented by:		
Cash - held by the entity	52 862	61 227
Cash - held in OPA	8 581 998	7 290 558
Total	<u>8 634 860</u>	<u>7 351 785</u>
<u>National Blood Account - Administered</u>		
Balance carried from previous year	126 723 721	80 494 223
Appropriation Act (No. 2)	3 952 000	1 605 000
Other receipts - Commonwealth contributions	401 748 158	355 848 145
Other receipts - States and Territory contributions	237 643 813	219 555 455
Other Receipts - External entities	-	3 405 800
GST credits (FMA s30A)	63 342 960	52 959 787
Available for payments	<u>833 410 652</u>	<u>713 868 410</u>
Payments made to suppliers	699 670 113	587 144 689
Balance carried to next period	<u>133 740 539</u>	<u>126 723 721</u>
Represented by:		
Cash transferred to the OPA	<u>133 740 539</u>	<u>126 723 721</u>

A special account is a mechanism used to record amounts in the Consolidated Revenue Fund (CRF) that are set aside for specified purposes.

The CRF is appropriated for the purposes of the Special Account, up to the balance of the Special Account. Transactions on Special Accounts are recorded as credits (which increase the balance and related appropriation) or debits (which reduce the balance of the Special Account and the related appropriation). Special Accounts are not administered items and are therefore excluded from the Schedule of Administered Assets and Liabilities.

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

	2007 \$	2006 \$
NOTE 23 Special Accounts (continued)		
NATIONAL MANAGED FUND (BLOOD AND BLOOD PRODUCTS)		
<i>Legal Authority: Financial Management and Accountability Act 1997 s20.</i>		
<i>Purpose: For the receipt of monies and payment of all expenditure related to the management of blood and blood products liability claims against the Australian Red Cross Society (ARCS) in relation to the activities undertaken by the operating division of the ARCS known as the Australian Red Cross Blood Service.</i>		
<u>National Managed Fund (Blood and Blood Products) - Administered</u>		
Balance carried from previous year	31 740 889	22 274 205
Appropriation Act (No.1)	1 981 000	1 486 000
Other receipts - Commonwealth contributions	4 936 114	4 936 114
Other receipts - States and Territory contributions	2 900 372	2 898 986
Other receipts - External entities	175 890	175 890
GST credits (FMA s30A)	1 386	-
Available for payments	<u>41 735 651</u>	31 771 195
Payments made to suppliers	<u>49 086</u>	30 306
Balance carried to next period	<u>41 686 565</u>	<u>31 740 889</u>
Represented by:		
Cash held in the OPA	<u>41 686 565</u>	<u>31 740 889</u>

OTHER TRUST MONEY SPECIAL ACCOUNT

Legal Authority: Financial Management and Accountability Act 1997 s20.

Purpose: For expenditure of monies temporarily held on trust or otherwise for the benefit of a person other than the Commonwealth.

Other Trust Money Special Account

Balance carried from previous year	3 165	-
Appropriation for reporting period	-	-
Other receipts - Related entities	-	22 510
Other receipts - External entities	-	-
GST credits (FMA s30A)	-	-
Available for payments	<u>3 165</u>	22 510
Payments made	<u>3 165</u>	19 345
Balance carried to next period	<u>-</u>	<u>3 165</u>
Represented by:		
Cash held in the OPA	<u>-</u>	<u>3 165</u>

A special account is a mechanism used to record amounts in The Consolidated Revenue Fund (CRF) that are set aside for specified purposes.

The CRF is appropriated for the purposes of the Special Account, up to the balance of the Special Account.

Transactions on Special Accounts are recorded as credits (which increase the balance and related appropriation) or debits (which reduce the balance of the Special Account and the related appropriation). Special Accounts are not administered items and are therefore excluded from the Schedule of Administered Assets and Liabilities.

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

NOTE 24 Compensation and Debt Relief

Administered

No Act of Grace payments were made during the reporting period.

No waivers of amounts owing to the Australian Government were made pursuant to subsection 34 (1) of the *Financial Management and Accountability Act 1997*.

No ex gratia payments were made during the reporting period.

Departmental

No payments were made under the Defective Administration Scheme during the reporting period.

No payments were made under s 73 of the *Public Service Act 1999* during the reporting period.

NATIONAL BLOOD AUTHORITY
NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
for the year ended 30 June 2007

Note 25 Reporting of Outcomes

Note 25A - Net cost of outcome delivery

Particulars	Outcome 1	
	2007 \$'000	2006 \$'000
Year ended 30 June 2007		
Administered	608 850	566 139
Departmental	9 059	7 628
Total expenses	617 909	573 767
<i>Costs recovered from provision of goods and services to the non-government sector</i>		
Administered	246 947	217 075
Departmental	4 064	3 570
Total costs recovered	251 011	220 645
Net cost/(contribution) of outcome	366 898	353 122

The National Blood Authority operates under one outcome and one output. Transactions reported under this output are reported in the Income Statement and the Balance Sheet.

Note 25B - Major classes of departmental revenues and expenses by output groups and outputs

Particulars	Output 1	
	2007 \$'000	2006 \$'000
Year ended 30 June 2007		
Departmental expenses		
Employees	5 712	4 859
Suppliers	2 941	2 395
Depreciation and amortisation	284	285
Other expenses	122	89
Total departmental expenses	9 059	7 628
Funded by:		
Revenues from government	6 065	4 532
Sales of goods and services	4 064	3 570
Other non-taxation revenue	96	91
Total departmental revenue	10 225	8 193

Note 25C - Major administered revenues and expenses by outcomes

Particulars	Outcome 1	
	2007 \$'000	2006 \$'000
Year ended 30 June 2007		
Administered revenues		
Sales of goods and services	223 957	213 875
Other non-taxation revenue	22 990	3 200
Total Administered Revenues	246 947	217 075
Administered Expenses		
Suppliers	303 080	266 843
Grants	305 770	299 296
Total Administered Expenses	608 850	566 139

6: Appendices

Appendix 2: Freedom of Information Statement

Section 8 of the *Freedom of Information Act 1982* requires that Australian Government agencies publish, in their annual report, information about:

- functions and decision-making powers that affect the public
- arrangements for public participation in the formulation of policy
- the categories of documents that are held by the agency
- how these documents can be accessed by the public.

Freedom of information statistics

In 2006–07 the National Blood Authority:

- received one request for access to documents under the Freedom of Information Act
- received no requests for internal review under the Freedom of Information Act
- was not involved in any Administrative Appeals Tribunal matters in respect of the Freedom of Information Act.

National Blood Authority functions and powers

Information on the organisation's structure and functions is included in this publication, as is performance information.

Ministers and the National Blood Authority's General Manager exercise decision-making powers under the *National Blood Authority Act 2003*. The National Blood Authority operates as an Australian Government agency where staff exercise functions and powers under Acts including the *Financial Management and Accountability Act 1997* and the *Public Service Act 1999*. Many decisions are given effect through contracts with suppliers which are administered by the National Blood Authority.

Arrangements for public participation

Under the National Blood Agreement, the primary responsibility for policy in the national blood products sector rests with the Australian Health Ministers' Conference, supported by the Jurisdictional Blood Committee.

In the performance of its functions, the National Blood Authority has established consultative forums, including a Clinical Advisory Council, a Professional and Community Forum and a Suppliers Forum. The National Blood Authority also undertakes consultation with a range of other expert bodies and interested parties for specific projects.

Categories of documents

The National Blood Authority maintains records relating to the performance of its functions. Records are retained for varying periods, depending on their administrative and historical value, and are disposed of in accordance with standards and practices approved by National Archives of Australia under the *Archives Act 1983*. The National Blood Authority holds the following categories of documents.

Category	Description
Program documents	The National Blood Authority holds documents relating to: contracts and tendering processes; dealings with Australian Government and state and territory ministers, committees and other government agencies under the National Blood Agreement; and the performance of its functions under the <i>National Blood Authority Act 2003</i> .
Working files	The National Blood Authority holds working files including correspondence, analysis and advice by National Blood Authority staff, documents received from third parties, and drafts of these and other documents.
Internal administration	The National Blood Authority holds personnel records, organisation and staffing records, financial and expenditure records, and internal operating documentation such as office procedures, instructions and indexes.
Documents open to public access subject to a fee or charge	The National Blood Authority holds no documents in this category.
Documents available for access or purchase subject to a fee or other charge	The National Blood Authority holds no documents in this category.
Documents customarily available free of charge upon request	The National Blood Authority's annual report and selected other documents relating to the National Blood Authority are available on the Internet, at www.nba.gov.au .

Procedures and contact details

A request for access to documents under the *Freedom of Information Act 1982* must be in writing. Applicants must enclose the \$30 application fee and state an address in Australia to which notices can be sent. In certain circumstances the fee is not required or can be remitted by the National Blood Authority.

To enable a prompt response and to help the National Blood Authority meet its obligations under the Freedom of Information Act, applicants should provide as much information as possible about the document(s) sought. It is also requested that the applicant include a telephone number or an electronic mail address to allow National Blood Authority staff handling a request to seek clarification if required. Applicants may be liable to pay charges at rates prescribed by the Freedom of Information (Fees and Charges) Regulations.

Inquiries about making a formal request under the Act should be directed to the National Blood Authority's Freedom of Information Coordinator, in writing to:

Freedom of Information Coordinator
 National Blood Authority
 Locked Bag 8430
 CANBERRA ACT 2601

Facilities for access

Physical access to documents can be arranged at the National Blood Authority's premises. Inquiries should be directed to the Freedom of Information Coordinator at the address above.

Appendix 3: Blood products supplied by the Australian Red Cross Blood Service

Product number	Fresh products supplied by the Australian Red Cross Blood Service
1a	Whole blood
1b	Whole blood - leucodepleted
2a	Whole blood red cell
2b	Whole blood red cell - leucodepleted
2c	Whole blood red cell - Buffy coat poor
2d	Whole blood paediatric red cell - leucodepleted (set of 4)
2e	Whole blood washed red cell
2f	Whole blood washed red cell - leucodepleted
2g	Apheresis red cell - leucodepleted
3a	Whole blood platelet
3b	Whole blood platelet pool - leucodepleted
3c	Whole blood platelet pool - Buffy coat poor
3d	Apheresis platelet - leucodepleted
3e	Paediatric apheresis platelet - leucodepleted (set of 4)
4a	Whole blood clinical fresh frozen plasma - standard
4b	Whole blood clinical fresh frozen plasma - Buffy coat poor
4c	Paediatric whole blood clinical fresh frozen plasma (set of 4)
4d	Apheresis clinical fresh frozen plasma
5a	Whole blood cryoprecipitate
5b	Apheresis cryoprecipitate
6a	Whole blood cryo-depleted plasma
6b	Apheresis cryo-depleted plasma
7a	Autologous donation
7b	Directed donation complying with Australian Health Ministers' Advisory Council Guidelines
7c	Therapeutic venesections for whole blood for discard
7d	Serum eye drops - 5ml or equivalent
7e	Granulocytes

Appendix 4: Plasma and recombinant products supplied under contract in 2006–07

List of products supplied under the Plasma Products Agreement

Supplier	Product type/trade name	Clinical use approved under the National Blood Arrangements
CSL Limited	Albumin	
	Albumex® 4	Used to treat hypovolaemia arising from shock, surgery or multiple organ failure
	Albumex® 20	Used to treat patients suffering extensive burns or shock due to blood loss, or kidney or liver disease
	Immunoglobulins	
	Hyper immune globulins	Used to prevent a specific infection such as tetanus, hepatitis B, Zoster or cytomegalovirus
	Intragam® P	Used to reduce susceptibility to infections and manage many immune system disorders
	Rh (D) ®	Used to prevent a potentially fatal form of anaemia in newborn babies of Rh (D) negative mothers
	Clotting factors	
	Biostat®	Used to treat Factor VII deficiency, known as haemophilia A
	MonofIX®-VF	Used to treat patients who have Factor IX deficiency, known as haemophilia B or Christmas disease
	Prothrombinex®-VF	Used to manage some bleeding disorders (concentrated clotting factors) and warfarin reversal
	Thrombotrol®-VF	Used to manage an inherited condition wherein a patient's blood clots too quickly

List of imported IVIg products

Supplier	Product type/trade name	Clinical use approved under the National Blood Arrangements
CSL Limited	Sandoglobulin®	Used to reduce susceptibility to infections and manage many immune system disorders
Octapharma Australia Pty Ltd	Octagam®	Used to reduce susceptibility to infections and manage many immune system disorders

List of imported rare bleeding and blood disorder plasma products

Supplier	Product type/trade name	Clinical use approved under the National Blood Arrangements
Baxter Healthcare Pty Ltd	Anti Inhibitor Coagulant Complex Concentrates/ FEIBA®	Used to treat bleeding episodes including surgical interventions in haemophilia A and B patients with inhibitors
Baxter Healthcare Pty Ltd	Protein C/Ceprotin®	Used to treat congenital Protein C deficiency
Baxter Healthcare Pty Ltd	FVII concentrate	Used to treat Factor VII deficiency
CSL Limited	FXI/BPL Factor XI LFB Hemoleven®	Used to treat people with Factor XI deficiency (sometimes called haemophilia C)
CSL Limited	FXIII/Fibrogammin P®	Used to treat people with Factor XIII deficiency
CSL Limited	Rh (D) Immunoglobulin/ WinRho®	Used to prevent haemolytic disease of the newborn (HDNB), a potentially fatal form of anaemia in newborn babies of Rh (D) negative mothers

List of imported rare bleeding and blood disorder recombinant products

Supplier	Product type/trade name	Clinical use approved under the National Blood Arrangements
Novo Nordisk Pharmaceuticals Pty Ltd	rFVIIa/NovoSeven®	Used to treat bleeding episodes including surgical intervention in haemophilia A or B patients with inhibitors to Factor VIII or Factor IX; also used to treat complex bleeding episodes in surgery, trauma and septicaemia
Baxter Healthcare Pty Ltd	rFVIII/Recombinate®	Used to treat Factor VIII deficiency, known as haemophilia A
Baxter Healthcare Pty Ltd	rFVIII/Advate®	Used to treat Factor VIII deficiency, known as haemophilia A
Wyeth Australia Pty Ltd	rFVIII/Refacto®	Used to treat Factor VIII deficiency, known as haemophilia A
Wyeth Australia Pty Ltd	rFIX/BeneFIX®	Used to treat patients who have Factor IX deficiency, known as haemophilia B or Christmas disease